跳至主要内容
临床试验/NCT00008320
NCT00008320已完成2 期

A Phase II Study Of Topical Ceramide Lipids As Treatment For Cutaneous Breast Cancer

Alliance for Clinical Trials in Oncology13 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2001年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
26
试验地点
13
主要终点
response rate

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of ceramide cream in treating women who have cutaneous breast cancer.

详细描述

OBJECTIVES: I. Determine the objective response rate in women with cutaneous breast cancer treated with topical ceramide cream. II. Determine the time to progression in patients treated with this regimen. III. Determine the toxicity of this regimen in these patients. IV. Assess the quality of life of these patients treated with this regimen.

OUTLINE: Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

ceramide cream

Experimental

Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.

干预措施: ceramide (Drug)

结局指标

主要结局

response rate

时间窗: up to 5 years

次要结局

  • time to progression(Up to 5 years)
  • quality of life(Up to 5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验